Visual Abstract

This study assessed the 5-year risk of diabetes complications of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/ml and lixisenatide, in type 2 diabetes (T2Ds) using a simulation model. The six-month efficacy data of iGlarLixi and Standard of Care (SOC) were extracted from the LixiLan-O trial and ORIGIN trial, and patients’ baseline characteristics were standardized to the ACCORD trial. The BRAVO diabetes simulation model was used to project the 5-year complications based on patients’ baseline characteristics and treatment efficacy. An optimistic scenario where the six-month relative efficacy of iGlarLixi (i.e., iGlarlixi-SOC) lasted for 5 years, and a conservative scenario where the relative effect of iGlarLixi waned to none within 5 years were simulated. iGlarLixi was found to reduce HbA1c (-1.4%), SBP (-3.4 mmHg), and BMI (-0.6 kg/m2) in six-month, compared with SOC. We found a 5-year risk reduction in major adverse cardiovascular events (MACE) (relative risk [RR] 77.1%, 95% CI: 66.9%-88.2%), and all-cause mortality (RR 94.0%, 95% CI:92.4%-96.3%) under an optimistic scenario, and MACE (RR 85.5%, 95% CI: 74.7%-96.3%), and all-cause mortality (RR 95.7%, 95% CI:92.1%-98.1%) under a conservative scenario (See Table for other outcomes). The long-term use of iGlarLixi may lead to a substantial reduction in diabetes-related complications among people with T2D at elevated risk for CVD.


H. Shao: Research Support; Self; Sanofi. H. Kianmehr: None. P. Li: None. V. Fonseca: Consultant; Self; Abbott Diabetes, Asahi Kasei Corporation, Bayer Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Intarcia Therapeutics, Inc., Novo Nordisk, Pfizer Inc., Sanofi-Aventis, Stock/Shareholder; Self; Amgen Inc., Bravo4health, Mellitus Health. L. Shi: Research Support; Self; AstraZeneca, Sanofi.


Sanofi (2020-1487)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at